Michael Thomas Henderson
Known title: DirectorCIK: 0001779990
Associated companies
Transaction History
| SYRE | ▼ Sell | Open Market | 20,000 | $2.0M | 6/22/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 2,404 | $174K | 5/8/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 33,513 | $2.5M | 5/8/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 19,269 | $1.5M | 5/8/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 24,814 | $1.9M | 5/8/2026 | View on chart |
| SYRE | ▼ Sell | Other | 63,227 | $0 | 1/21/2026 | View on chart |
| SYRE | ▼ Sell | Other | 105,379 | $0 | 1/10/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Spyre Therapeutics Launches $350M Public Offering, Stock Drops
Spyre Therapeutics has priced a $350 million public offering of common stock, which led to a decline in the share price on the launch day. The company also announced inducement awards to support its growth. Analysts from JP Morgan and BTIG have begun coverage, citing a target price around $110 to $121. The offering and analyst interest may influence the stock’s short‑term trajectory.
Spyre Therapeutics Launches $350M Public Offering, Stock Drops. Spyre Therapeutics has priced a $350 million public offering of common stock, which led to a decline in the share price on the launch day. The company also announced inducement awards to support its growth. Analysts from JP Morgan and BTIG have begun coverage, citing a target price around $110 to $121. The offering and analyst interest may influence the stock’s short‑term trajectory.